Biomarkers in Heart Failure and Acute Kidney Injury (CE: 1.0)

This program discusses the incidence and implications of acute kidney injury (AKI), including new biomarkers that can predict patient risk for AKI, which could allow physicians to intervene and potentially avoid the morbidity and mortality associated with the condition. Also discussed are heart failure biomarkers and their advantages and limitations in heart failure patients being treated with the new heart failure drug ENTRESTO. 

Presenter: Robert A. Elverson, MMGT, BS MT(ASCP), Senior Manager, Assay Market Development, Ortho Clinical Diagnostics, Raritan, NJ.